BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy-Reference-Cited by-同舟云学术

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Published:2021-05 Issue: Volume:149 Page:211-221
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Wiesweg Marcel^ORCID,Preuß Cedric^ORCID,Roeper Julia,Metzenmacher Martin,Eberhardt Wilfried,Stropiep Ursula,Wedeken Katrin,Reis Henning,Herold Thomas,Darwiche Kaid^ORCID,Aigner Clemens^ORCID,Stuschke Martin,Schildhaus Hans-Ulrich^ORCID,Schmid Kurt W.,Falk Markus,Heukamp Lukas,Tiemann Markus,Griesinger Frank,Schuler Martin

Funder

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

2. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall;Leonetti;Canc Treat Rev,2018

3. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS;Yao;Nature,2017

4. RAF kinase dimerization: implications for drug discovery and clinical outcomes;Brummer;Oncogene,2020

5. BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition;Yao;Canc Cell,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08

2. The evolving treatment landscape for BRAF-mutated non-small cell lung cancer;Translational Lung Cancer Research;2024-04

3. Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review;Frontiers in Oncology;2024-03-27

4. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

5. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia);Journal of Thoracic Oncology;2023-11